Back to Search
Start Over
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
- Source :
- ResearcherID, Publons
- Publication Year :
- 2015
-
Abstract
- 8073 Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We perform...
- Subjects :
- Pulmonary and Respiratory Medicine
Brachial Plexus Neuritis
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Afatinib
Medizin
non-small cell lung cancer (NSCLC)
Hematology
Pharmacology
medicine.disease
stomatognathic diseases
Tolerability
Egfr mutation
Dose adjustment
Internal medicine
medicine
In patient
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- ResearcherID, Publons
- Accession number :
- edsair.doi.dedup.....bb37b9cb5e343f7a3f9eb6a7f57da839